

The ISGIDAR NEWSLETTER

VOL. 31, NO. 2

November, 2005

<i>President of ISGIDAR</i>	<i>Secretary of ISGIDAR</i>
Richard W. Foltin, Ph.D. Department of Psychiatry College of Physicians and Surgeons of Columbia University 1051 Riverside Dr., Unit 120 New York, NY 10032 (212) 543-5717 rwf2@columbia.edu	Elise Weerts, Ph.D. Department of Psychiatry Johns Hopkins Univ. School of Medicine 5510 Nathan Shock Drive Suite 3000 Baltimore, MD 21224 (410) 550-2781 eweerts@jhmi.edu
<i>Chief Technology Officer</i>	<i>Treasurer of ISGIDAR</i>
Jonathan B. Kamien, Ph.D. BioPsych Consulting 3450 Vista Haven Road Sherman Oaks, CA 91403 email: jkamien@biopsych.com	Marilyn E. Carroll, Ph.D. Dept. of Psychiatry University of Minnesot Box 392 UMHC Minneapolis, MN 55454 (612) 626-6289 email: mcarroll@staff.tc.umn.edu

ISGIDAR e-mail address: ISGIDAR-L@venus.vcu.edu

INDEX

[2005 ISGIDAR SCIENTIFIC MEETING - Orlando, FL](#)

[2006 ISGIDAR SCIENTIFIC MEETING - Scottsdale, AZ](#)

[RECENT PUBLICATIONS](#)

[POSITIONS AVAILABLE](#)

2005 ISGIDAR SCIENTIFIC MEETING Orlando, FL

The 2005 annual ISGIDAR Scientific Meeting was held Sat. June 18th at the Wyndham PalaceHotel immediately preceding the annual scientific meeting of the College on Problems of DrugDependence.

Minutes of the 2005 Business meeting

Following a very full program of excellent talks, Dr. Nader opened the business meeting. The business meeting was well attended (about 55).

After distribution of beverages, nominations were taken for the next secretary and president. Our former secretary, Dr. Richard Foltin, was unanimously elected as the new President. Dr. Elise Weerts was nominated and elected as Secretary.

Dr. Marilyn Carroll gave the treasurer's report. Finances remain in the black. Dr. Carroll will continue on as the Treasurer.

Dr. Foltin raised the issue that we do not actually have an accurate record of all members. He would like to begin an actual directory of ISGIDAR members. *[Note: Since the business meeting Dr. Foltin and Kamien have been working on this. There are currently 129 members on the list serve. However, since not all members are on the listserv it will be difficult to determine to total number of members. See the letter from the President below.]*

There was also discussion of the ISGIDAR bylaws. According to the bylaws, there should be a vice president. No one currently holds that office. No one at the meeting thought a vice president was needed, so there was some discussion of changing the bylaws to better match current practices. The issue was deferred to a later vote, once members had time to review the bylaws. The bylaws can be viewed at the ISGIDAR website (http://www.isgidar.org/ISGIDAR_bylaws.htm).

Seven new members were elected

- Jenn Martelle
- Bill Kowalczyk
- Paul Vesina
- Larry Carter
- Rayna Bauzo
- Sarah Ewing
- Porche' Kirkland

A few Comments from the President

Our past President, Dr. Nader, like all of the past Presidents, did an excellent job of guiding this collection of scientific vagabonds forward for two years. I hope to do so as well, and at least leave the organization no worse off than when I started.

It is never too early to think about next year and Scottsdale, AZ. I have already had several people ask about presentations. There is also room for a symposium if someone wants to pursue organizing one. In the past, these have been well received, and they are a nice addition to the program.

Looking for newsletters

I have scanned all of the ISGIDAR newsletters that I could find and Jonathan Kamien has placed them on the website (<http://www.isgidar.org>; in fact Dr. Nader did such a good job, Jonathan has kept him as President on the website!). We are still missing a few. If anyone has any of the following newsletters (1990, 1991, 1992) in their files, can you please send me an electronic copy, or the actual newsletter?

- 16 (1)
- 16 (2)
- 17 (1)
- 17 (2)

My contact information is proudly displayed at the top of the newsletter.

Richard Folton, Ph.D.
ISGIDAR President

Looking for current and past ISGIDAR members

We are trying to get an accurate list of members. Earlier this year I e-mailed the ISGIDAR mailing list and CPDD mailing list asking people to confirm membership and provide updating information. I heard from about 100 people. With this mailing, our esteemed Secretary is attaching a list (somewhat messy) that contains all the people on the old mailing label list who have not confirmed membership. Please look at the list, and contact anyone you know on the list, and ask them to contact me, if they wish to stay in our good graces. Feel free to use the following plea:

“ISGIDAR is updating their membership list with the goal of using all electronic communication. Your name is on an old list of members who used to get USPS mail from ISGIDAR. Please e-mail Richard W. Foltin (rwf2@columbia.edu) to tell him of your ISGIDAR status. Even if you no longer come to the meetings and do not wish to be involved, please let Richard know, so he can remove your name from the active list. If you wish to stay with the group, you will get some e-mails from the LISTSERV each year, but the number will be small. Thanks”

2006 ISGIDAR SCIENTIFIC MEETING— Scottsdale AZ

The 2006 annual ISGIDAR Scientific Meeting will be held Saturday June 17th in Scottsdale, Arizona. As usual, the meeting will be held as a satellite session immediately preceding the annual scientific meeting of the College on Problems of Drug Dependence.

Recent Publications

Nancy Ator

- Ator, N.A. (2005) Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. *CNS Spectrums*, 10: 31-39.
- Ator, N.A., Griffiths, R.R., Weerts, E. M. (2005) Self-injection of flunitrazepam alone and in the context of methadone maintenance in baboons. *Drug and Alcohol Dependence* 78(2):113-123

George Bigelow

- Donny EC, Brassler SM, Bigelow GE, Stitzer ML, Walsh SL. (2005) Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. *Addiction*. 100(10):1496-509.
- Correia CJ, Sigmon SC, Silverman K, Bigelow G, Stitzer ML. (2005) A comparison of voucher-delivery schedules for the initiation of cocaine abstinence. *Exp Clin Psychopharmacol*. 13(3):253-8.
- Jones HE, Johnson RE, Bigelow GE, Silverman K, Mudric T, Strain EC. (2004) Safety and efficacy of L-tryptophan and behavioral incentives for treatment of cocaine dependence: a randomized clinical trial. *Am J Addict*. 13(5):421-37.
- Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE. (2004) Evaluation of an injection depot formulation of buprenorphine: placebo comparison. *Addiction*. 99(11):1439-49.
- Silverman K, Robles E, Mudric T, Bigelow GE, Stitzer ML. (2004) A randomized trial of long-term reinforcement of cocaine abstinence in methadone-maintained patients who inject drugs. *J Consult Clin Psychol*. 72(5):839-54. Hendrix CW, Wakeford J, Wire MB, Lou Y, Bigelow GE, Martinez E, Christopher J, Fuchs EJ, Snidow JW. (2004) Pharmacokinetics and

pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. *Pharmacotherapy*. 24(9):1110-21.

- Strain EC, Moody DE, Stoller KB, Walsh SL, Bigelow GE. (2004) Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. *Drug Alcohol Depend*. 74(1):37-43.
- Sobel BF, Sigmon SC, Walsh SL, Johnson RE, Liebson IA, Nuwayser ES, Kerrigan JH, Bigelow GE. (2004) Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. *Drug Alcohol Depend*. 73(1):11-22.
- Donny EC, Bigelow GE, Walsh SL. (2004) Assessing the initiation of cocaine self-administration in humans during abstinence: effects of dose, alternative reinforcement, and priming. *Psychopharmacology (Berl)*. 172(3):316-23.
- Houtsmuller EJ, Notes LD, Newton T, van Sluis N, Chiang N, Elkashef A, Bigelow GE. (2004) Transdermal selegiline and intravenous cocaine: safety and interactions. *Psychopharmacology (Berl)*. 172(1):31-40.

Zuzana Justinova

- Justinova Z, Solinas M, Tanda G, Redhi GH, Goldberg SR (2005). The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. *J Neurosci*. 25(23):5645-50.
- Justinova Z, Goldberg SR, Heishman SJ, Tanda G. (2005) Self-administration of cannabinoids by experimental animals and human marijuana smokers. *Pharmacol Biochem Behav*. 81(2):285-99.
- Yasar S, Gaal J, Justinova Z, Bergman J. (2005) Discriminative stimulus and reinforcing effects of p-fluoro-L-deprenyl in monkeys. *Psychopharmacology (Berl)*. 182(1):95-103.

Robert Malison

- Sughondhabirom A, Jain D, Gueorguieva R, Coric V, Berman R, Lynch WJ, Self D, Jatlow P, Malison RT (2005). A paradigm to investigate the self-regulation of cocaine administration in humans. *Psychopharmacology* 180:436-446

Ken Perkins

- Conklin, C.A., & Perkins, K.A. (2005) Subjective and reinforcing effects of smoking during negative mood induction. *Journal of Abnormal Psychology*, 114, 153-164.

- Rukstalis, M., Jepson, C., Strasser, A., Lynch, K.G., Perkins, K.A., Patterson, F. & Lerman, C.A. (2005) Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. *Psychopharmacology*, 181, 41-48.
- Chaudhri, N., Caggiula, A.R., Donny, E.C., Booth, S., Gharib, M.A., Craven, L.A., Allen, S.S., Sved, A.F., & Perkins, K.A. (2005) Sex differences in the contribution of nicotine and nonpharmacological stimuli to nicotine self-administration in rats. *Psychopharmacology*, 180, 258-266.
- Blendy, J.A., Strasser, A., Walters, C.L., Perkins, K.A., Patterson, F., Berkowitz, R., & Lerman, C. (2005) Reduced nicotine reward in obesity: cross comparison in human and mouse. *Psychopharmacology*, 180, 306-315.
- Conklin, C.A., Perkins, K.A., Sheidow, A.J., Jones, B.L., Levine, M.D., & Marcus, M.D. (2005) The return to smoking: One year relapse trajectories among female smokers. *Nicotine and Tobacco Research*, 7, 533-540.
- Perkins, K.A., Doyle, T.D., Ciccocioppo, M., Conklin, C., Sayette, M., & Caggiula, A. Sex differences in the influence of nicotine dose instructions on the reinforcing and self-reported rewarding effects of smoking. *Psychopharmacology*, in press.
- Perkins, K.A., Stitzer, M., & Lerman, C. Medication screening for smoking cessation: a proposal for new methodologies. *Psychopharmacology*, in press.

Jennifer Tidey

- Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. (2005) Subjective and physiological effects of smoking cues in outpatients with schizophrenia. *Nicotine and Tobacco Research*, 7, 421-429.
- Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. (2005) Smoking topography in smokers with schizophrenia and matched non-psychiatric controls. *Drug and Alcohol Dependence*, 80, 259-265.

Elise Weerts

- Weerts, E.M., Goodwin, A.K., Griffiths, R.R., Brown, P.R., Froestl, W., Jakobs, C., Gibson, K.M. (2005) Spontaneous and precipitated withdrawal after chronic intragastric administration of gamma-hydroxybutyrate (GHB) in baboons. *Psychopharmacology* 179(3): 678-687
- Goodwin, A.K., Froestl, W., Weerts, E.M. (2005) Involvement of GHB and GABAB receptors in the behavioral effects of gamma-hydroxybutyrate (GHB) in Baboons. *Psychopharmacology*. 180(2):342-351
- Hienz, R.D., Weerts, E.M. (2005) Cocaine's effects on the perception of socially significant vocalizations in baboons. *Pharmacology Biochemistry and*

Behavior, 81(3):440-450 Munroe, C.A., Oswald, L., Weerts, E., McCaul, M.E., Wand, G. (2005) Hormone responses to social stress in abstinent alcohol-dependent subjects and social drinkers with no history of alcohol dependence. *Alcoholism: Clinical and Experimental Research*, 29(7):1133-1138

- Weerts, E.M., Ator, N.A., Kaminski, B.J., Griffiths, R.R. (2005) Comparison of the behavioral effects of bretazenil and flumazenil in triazolam dependent and non-dependent baboons. *European Journal of Pharmacology* 519: 103-113
- Weerts, E.M., Froestl, W., Griffiths, R.R. (2005) Effects of GABAergic modulators on food and cocaine self-administration in baboons. *Drug and Alcohol Dependence*, Available Online [Epub ahead of print]

Gerald Zernig

- J. A. Crespo, K. Sturm, A. Saria, and G. Zernig. Simultaneous intra-accumbens remifentanil and dopamine kinetics suggest that neither determines within-session operant responding. *Psychopharmacology* (<http://dx.doi.org/10.1007/s00213-005-0180-7>):1-9, 2005.
- J. A. Crespo, L. V. Panlilio, C. W. Schindler, K. Sturm, A. Saria, and G. Zernig. Peri-responsepharmacokinetics of remifentanil during a self-administration session indicates that blood or brain levels are not titrated. *Ann N Y Acad. Sci.*, under revision, 2005.

POSITIONS AVAILABLE

PSYCHOLOGY FACULTY POSITION – VIRGINIA COMMONWEALTH UNIVERSITY

Virginia Commonwealth University is seeking a psychologist for a joint appointment in the Department of Psychology and the Massey Cancer Center, for a tenure-track, rank-open position (position contingent upon the availability of funding). Applicants must have a Ph.D. in psychology, and be actively engaged in research in an area of cancer prevention and control. We seek an energetic scholar who will contribute to teaching, research, and mentoring in both the Department of Psychology and the Massey Cancer Center, which is a National Cancer Institute designated Cancer Center, including significant involvement in an NCI-funded Cancer Control Training Program and active participation in the Massey Cancer Center Cancer Control Program. Strong preference will be given to applicants with (a) established research programs with active funding, or high potential for funding in cancer control research in areas of current focus at Massey Cancer Center, including but not limited to

prevention, diet and exercise, tobacco-related studies, or palliative care; (b) the credentials to affiliate with and contribute to at least one of the Department of Psychology's existing programs; and (c) evidence of the ability to develop cross-disciplinary research and collaboration. Candidates must show evidence of success in publishing their work in refereed journals and edited volumes. There is a rich opportunity to collaborate with colleagues in Psychology and the Massey Cancer Center, as well as other disciplines and schools at VCU, such as the Institute for Drug and Alcohol Studies and the university's new School of Public Health. The Department of Psychology is composed of three programs, including Clinical and Counseling Psychology (both APA-accredited), and the General Experimental program (with Biopsychology, Developmental Psychology, and Social Psychology divisions). Applicants should submit a statement of research interests, teaching philosophy and interests, a current curriculum vita, representative publications, and at least three letters of reference to Dr. Steve Danish Co-Chair of the Search Committee, at Virginia Commonwealth University, Department of Psychology, PO Box 842018, Richmond, Virginia 23284. Additional information about the Department of Psychology can be found at <http://www.has.vcu.edu/psy/>, and about the Massey Cancer Center at <http://www.vcu.edu/mcc/>. Application review will begin on January 6, 2006 and continue until the position is filled.

Virginia Commonwealth University is an equal opportunity/affirmative action employer. Women, minorities and persons with disabilities are encouraged to apply.

POST-DOCTORAL POSITION IN SUBSTANCE ABUSE RESEARCH AT JOHNS HOPKINS UNIVERSITY

Postdoctoral research fellowships in stimulating, productive program with excellent resources. Prepare as independent investigator.

HUMAN LABORATORY -- behavioral & clinical pharmacology of abused drugs (abuse liability, self-administration, cognitive function, neuroimaging); anti-drug-abuse medications development. Opioids, cocaine, anxiolytics, alcohol, caffeine, nicotine, hallucinogens (psilocybin, DMT).

CLINICAL TRIALS – testing medications, verbal & behavioral therapies (esp. incentive/motivation-based), and combinations; psychiatric comorbidity research; addiction & pregnancy/women. Opioid, cocaine, tobacco, mixed/other dependencies.

Start Date: Flexible.

Eligibility: citizen, permanent resident. A broad range of backgrounds are appropriate – from clinical/counseling to experimental/neuroscience.

NIH stipend levels: \$35K - 51K+.

Contact George Bigelow, Roland Griffiths, or Maxine Stitzer; BPRU, Behavioral Biology Research Center; 5510 Nathan Shock Drive; Johns Hopkins Bayview

Campus; Baltimore, Maryland 21224-6823. (410) 550 0035; bigelow@jhmi.edu.
See www.bpru.org

POST-DOCTORAL POSITION IN HUMAN BEHAVIORAL PHARMACOLOGY OF NICOTINE

A post-doctoral position in the behavioral pharmacology of nicotine in humans may be available in the laboratory of Dr. Kenneth A. Perkins at the University of Pittsburgh. This position is funded through NHLBI. Ongoing NIDA-supported projects focus on: 1) environmental modulation of nicotine responses and tobacco self-administration, 2) individual differences associated with sensitivity to nicotine, including gender, genetic, and personality factors. Applicants also interested in clinical research may become involved in smoking cessation studies.

Interested candidates should send a C.V. and letter of interest to Dr. Perkins at the following address:

Kenneth A. Perkins, Ph.D.
Department of Psychiatry
University of Pittsburgh Medical Center
3811 O'Hara Street
Pittsburgh, PA 15213

voice: (412) 246-5395
fax: (412) 246-5390
email: perkiska@upmc.edu
website: <http://myprofile.cos.com/perkinsk31>

POSTDOCTORAL FELLOWSHIPS IN ALCOHOL ABUSE AND ADDICTIONS RESEARCH BROWN MEDICAL SCHOOL, CENTER FOR ALCOHOL AND ADDICTION STUDIES

The Center for Alcohol and Addiction Studies at the Brown Medical School is recruiting for fellows in two associated postdoctoral fellowship training programs, one funded by NIAAA in alcohol abuse and addictions and one funded by NIDA in substance abuse. The training programs provide postdoctoral research training for biomedical, behavioral, and social scientists and health care professionals who wish to conduct high quality research in the early intervention and treatment of alcohol and other drug problems. Areas of expertise in the fellowship include pharmacotherapy, neurobiology and genetics of alcohol and substance dependence, and animal models of alcohol and drug reinforcement, consumption, sensitization and conditioned reward.

Application review begins on January 17, 2006. For further details and an application go to <http://www.caas.brown.edu>

**POSTDOCTORAL FELLOWSHIP –UNIVERSITY OF MIAMI MILLER
SCHOOL OF MEDICINE**

A postdoctoral fellowship position is available immediately at the University of Miami Miller School of Medicine to study the behavioral and neurochemical effects of drugs of abuse. Current emphasis is on interactions between opioids and cocaine and other psychostimulants on behavior and neurochemistry. Studies include drug self-administration, locomotor activity, receptor binding, uptake, and second messenger function of dopamine and opioid receptors. Applicants should have a strong interest in learning to do neurochemical assays and in integrating behavioral and neurochemical studies. Experience with self-administration is desirable and experience with laboratory animals is essential.

Please contact: Sari Izenwasser, Ph.D.
Dept. of Psychiatry (D-80)
Univ. Miami Sch. of Med.
1400 NW 10th Ave, Room 704A
Miami, FL 33136
s.izenwasser@miami.edu